Pharmaceutical industry – Page 10
-
BusinessBrewing up plant-inspired medicines
Antheia reconstructs complex biochemical pathways in yeasts to speed up production of natural product-based drugs
-
WebinarFind robust operating points using JMP’s Simulation Experiment tool
Learn how simulations can be used to minimise defect rate and improve crucial targets
-
BusinessDeveloping countries sidelined in Covid-19 vaccine scramble
Lack of funds and local manufacturing capacity has prevented Covax from competing with wealthier nations’ self-interest
-
ArticlePeople, partnerships, pharma: exploring the science of innovation
The importance of fostering collaborative cultures to accelerate innovation
-
ArticlePeptones: over 100 years of life-saving innovation
After a century, peptones continue to play a vital role in biopharmaceutical innovation
-
BusinessPfizer backs protein degrader drugs with Arvinas deal
$1bn investment to commercialise breast cancer treatment
-
WebinarThe era of data analytics: What it takes to succeed beyond the hype
Find out how to make better decisions about your data using analytics and subject matter knowledge
-
OpinionPutting combustion into reverse
Unburning carbon dioxide economically and at scale is a tough problem, but potentially world-changing
-
BusinessIndustry tightens emissions reduction targets
As COP26 approaches, many firms are announcing ambitious climate goals. But are they achievable?
-
OpinionKathleen Culhane Lathbury – an industrial pioneer
Nina Notman tells the story of the interwar industrial chemist whose analytical skill and persistence saw her outmanoeuvre sexism and prove her research aptitude
-
OpinionOpening up a cellular black box
Working out how biomolecular condensates work may reveal a lot about the success or failure of different drugs
-
BusinessSartan contaminant recall hits generics manufacturers
Three European suppliers recalling multiple batches of medicines owing to active ingredient contamination
-
BusinessUS judge rules against GSK in trade secrets dispute
Firm will not receive compensation for claimed loses of over $1bn from theft of confidential information by two former scientists
-
BusinessBMS and Eisai agree antibody-drug conjugate commercialisation deal
Companies will jointly develop cancer treatment, with BMS paying up to $3 billion for shared rights
-
BusinessRegeneron’s Covid-19 antibodies help those who can’t make their own
Regn-Cov2 reduces deaths and shortens hospitalisation for these patients, even when given at late stages of infection
-
BusinessAlzheimer’s antibody gets surprise US approval
Good news for industry and future drug approvals, but physicians doubt it will be effective for most patients
-
ResearchProtein impurities found in AstraZeneca’s Covid-19 vaccine stir debate
Compounds might cause side effects but are unlikely to be behind extremely rare blood-clotting events
-
BusinessMorphosys agrees to buy cancer epigenetics specialist Constellation
$1.7bn deal will be funded by selling rights to royalties on existing drugs
-
BusinessUS supreme court will not hear J&J talc appeal
Decision means J&J must pay $2.1 billion previously awarded to 22 women who say talc caused their ovarian cancer
-
WebinarThe age of digital chemistry
Join us to learn how data can solve existing bottlenecks in synthetic chemistry and why data analysis demands a multidisciplinary approach